Business
Institutional Fundraise
Hemogenyx Pharmaceuticals plc has successfully raised £3,000,000 through a direct subscription of 374,532 new ordinary shares at £8.01 each, with net proceeds designated to accelerate Phase I clinical trials for its HG-CT-1 therapy, targeting relapsed/refractory acute myeloid leukaemia in adults and children. The company is also progressing its early commercialisation strategy for HG-CT-1 in Estonia, having established the necessary manufacturing hardware and infrastructure and preparing for technology transfer with Cellin Technologies OÜ. Admission of the new shares to the London Stock Exchange is anticipated around May 6, 2026, at which point the enlarged issued share capital will be 6,799,961 ordinary shares. Disclaimer*
About this update from Hemogenyx Pharmaceuticals Plc
28 April 2026 THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED. ON PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN. Hemogenyx Pharmaceuticals plc ("Hemogenyx Pharmaceuticals" or the "Company") Hemogenyx Secures £3,000,000 to accelerate its Phase 1 Clinical Trials and initiate early commercialization of HG-CT-1 Hemogenyx Pharmaceuticals plc (LSE: HEMO) is pleased to announce that it has raised £3,000,000 from a small group of institutional investors to support the acceleration of its clinical development programmes. The fundraising was completed through a direct subscription for 374,532 new ordinary shares in the Company at a market bid price at closing of trading on April 27 of £8.01 per share. The net proceeds from the fundraising will be used primarily to accelerate the Phase I clinical trials of the Company's proprietary Chimeric Antigen Receptor T-cell therapy, HG-CT-1. This therapy is being developed for the treatment of relapsed/refractory acute myeloid leukaemia ("R/R AML") in adults and is now also being extended into paediatric patients. Early Commercialisation Initiative In September 2025, the Company announced that it had begun exploring the potential for early commercialisation of HG-CT-1 through the hospital exemption pathway under Estonia's Medicinal Products Act. The Company is pleased to report that the necessary hardware and infrastructure for the manufacturing of HG-CT-1 in Estonia have now been established. Hemogenyx, in collaboration with its Estonian partner Cellin Technologies OÜ, intends to commence the technology transfer process required for local manufacturing of HG-CT-1 imminently. The successful completion of this fundraising provides the Company with additional financial resources to advance its clinical programmes and progress its early commercialisation strategy for HG-CT-1. Further updates will be provided in due course. An application is being made to the Main Market of the London Stock Exchange, and admission of the Placing Shares to trading is expected on or around May 6, 2026 ("Admission"). The Placing Shares will rank pari passu with the Compa...
View stock analysis, news, and events for Hemogenyx Pharmaceuticals Plc